GAITHERSBURG, Md. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Vipin K. Garg , Ph.D., President and Chief Executive Officer will present at the Cowen 40 th Annual Health Care Conference in Boston on Monday, March

GAITHERSBURG, Md. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:     2020 BIO CEO & Investor Conference Date:    Monday, February

Preclinical study shows systemic activity of ALT-702 following local administration Altimmune granted U.S. patent providing broad coverage of platform technology GAITHERSBURG, Md. , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company today

GAITHERSBURG, Md. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference being held on January 9-11, 2020 in Park City, Utah.  Details for the oral presentation are as